| |
 |
 |
 |
 |
 |
 |
 |
October 14, 2003
AnGes MG
and Hokkaido System Science Co., Ltd. establish corporate alliance
-Granting of manufacture and marketing
rights for NF B
decoy oligo reagent- |
 |
|
|
Today AnGes MG, Inc. concluded a licensing agreement
with Hokkaido System Science Co., Ltd., which specializes in
nucleic acid synthesis. According to this agreement, AnGes MG
licenses the manufacture and marketing of NF B
decoy oligo patented in the USA; patent pending in Japan, for
subsequent use as a reagent.
NFB
decoy oligo is an artificially-synthesized double-stranded nucleic
acid which is 20 base pairs long and has the same sequences
that naturally occur in genes. It regulates the expressions
of cytokines and adhesion factors responsible for cancers and
immune inflammatory diseases by inhibiting the transcription
factor NFB.
AnGes MG has been developing NFB
decoy oligo as a therapeutic agent for atopic dermatitis and
articular rheumatism as well as a prophylactic agent for restenosis.
Various basic research aiming at clarifying the disease mechanisms
of cancers and immune inflammatory diseases, researches focusing
on NFB
have been carried out at reserch institutions in Japan as well
as abroad. AnGes MG therefore has opted to enter into a corporate
alliance with Hokkaido System Science to develop and supply
reagents for public research institutions such as universities,
believing that the Company can make a valuable contribution
to basic research relating to these diseases and the development
of therapeutic agents, through the use of NFB
decoy oligo which can inhibit NFB.
The alliance with Hokkaido System Science for the manufacture
and marketing of NFB
decoy oligo as a research reagent will enable AnGes MG to supply
the research reagent of NFB
decoy oligo to research institutions throughout Japan as well
as abroad.
The royalties from Hokkaido System Science will contribute to
the Company's revenue.
The effect of the cooperative agreement on the Company's earnings
cannot be determined at present. |
| Reference |
|
|
|
1. NFB
(nuclear factor-kappa B)
NFB
is a genetic factor enabling regulation of cytokines and adhesion
factors - related to immunological reactions. Bonding NFB
to a genome causes excessive transcription of immunization-related
genetic expressions. This is why NFB
has been indicated as one of the causes of atopic dermatitis
and rheumatic arthritis.
2. NFB
decoy oligo (NF kappa B decoy oligodeoxynucleotide)
A genetic expression features a switch - transcriptional factor
- bonded to a genome. A decoy is an artificial gene (also referred
to as nucleotide) in which a "compressed" nucleic
acid of the same genetic sequences as the aforementioned transcriptional
factor is artificially synthesized, which when introduced to
the body, neutralizes those "switches" by preventing
their bonding to a genome, thereby regulating the transcription
process.
It is a decoy nucleotide against NFB.
AnGes MG is developing therapeutic agents on the basis of its
properties to treat patients suffering from atopic dermatitis,
rheumatic arthritis, and restenosis - conditions caused by excessive
immunological response. |
| Company
Profile |
|
|
|
| Corporate name: |
Hokkaido System Science Co.,LTD |
| Head office: |
1-1-34, 14-jyo Hassamu, Nishi-ku, Sapporo, Hokkaido,
063-0834 Japan |
| President and CEO: |
Yukio Mizutani |
| Established: |
September, 1988 |
| Capital: |
126 million yen (September 2003) |
| Number of employees: |
95 (September 2003) |
| Sales: |
1,086 million yen (for 2002) |
| Scope of business: |
Contracting of DNA synthesis, DNA sequencing, etc. |
|
|
| Corporate name: |
AnGes MG, Inc. |
| Head office: |
1-4-2 Shin-senri Higashi-Machi, Toyonaka-shi, Osaka,
560-0082 Japan |
| President and CEO: |
Ei Yamada |
| Established: |
December, 1999 |
| Capital: |
4,760 million yen (October 10, 2003) |
| Number of employees: |
62 (June 2003) |
| Sales: |
1,794 million yen (for 2002) |
| Scope of business: |
Research and development of genetic medication |
|
|
|
